Jan Pander
Overview
Explore the profile of Jan Pander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pander J, Termorshuizen F, de Lange D, Beekman-Hendriks W, Lanfermeijer J, Bakhshi-Raiez F, et al.
Infect Dis Ther
. 2025 Mar;
PMID: 40085166
Introduction: The corona virus disease 19 (COVID-19) pandemic has presented a global health challenge, and several consecutive variants of the severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2) virus have been dominant....
2.
Pander J, Beekman-Hendriks W, Coolen N, van de Flier V, Senster J, Rovers C
Prev Med Rep
. 2024 Aug;
45:102827.
PMID: 39114410
Objectives: In March 2023, all societal-level COVID-19 control measures were lifted by the Dutch government. This study was performed to understand the self-experienced burden of this new phase of COVID-19...
3.
Vervloet M, de Jong H, Pander J, Overbeek J
BMC Nephrol
. 2023 Nov;
24(1):337.
PMID: 37957561
Background: Knowledge on prevalence, comorbidities and consequences of chronic kidney disease (CKD) is mandatory to estimate the potential of cardiovascular risk management on a population level. We studied the prevalence...
4.
Pander J, van Huis-Tanja L, Bohringer S, der Straaten T, Gelderblom H, Punt C, et al.
PLoS One
. 2015 Jul;
10(7):e0131091.
PMID: 26222057
Purpose: Despite expanding options for systemic treatment, survival for metastatic colorectal cancer (mCRC) remains limited and individual response is difficult to predict. In search of pre-treatment predictors, pharmacogenetic research has...
5.
Pander J, Heusinkveld M, der Straaten T, Jordanova E, Baak-Pablo R, Gelderblom H, et al.
Clin Cancer Res
. 2011 Jul;
17(17):5668-73.
PMID: 21788356
Purpose: In a recent randomized phase III clinical trial in metastatic colorectal cancer patients, the addition of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) cetuximab to bevacizumab and...
6.
Pander J, Guchelaar H, Gelderblom H
Curr Opin Mol Ther
. 2010 Dec;
12(6):654-61.
PMID: 21154157
Cancer treatment has undergone revolutionary changes during the past decade, as a result of the introduction of tyrosine kinase inhibitors (TKIs) that selectively inhibit growth factor pathways critical for tumor...
7.
Pander J, Wessels J, Mathijssen R, Gelderblom H, Guchelaar H
Pharmacogenomics
. 2010 Jul;
11(7):1011-7.
PMID: 20602619
Disappointing results from replicating pharmacogenetic association studies have prompted the search for novel statistical techniques to analyze the data, while taking into account the biological complexity underlying drug response. Two...
8.
Pander J, Gelderblom H, Antonini N, Tol J, van Krieken J, der Straaten T, et al.
Eur J Cancer
. 2010 Apr;
46(10):1829-34.
PMID: 20418097
Background: Next to KRAS mutation status, additional predictive markers are needed for the response to cetuximab in patients with metastatic colorectal cancer (mCRC). Previous studies indicated that germline polymorphisms in...
9.
Van Nieuwkoop C, Vant Wout J, Assendelft W, Elzevier H, Leyten E, Koster T, et al.
BMC Infect Dis
. 2009 Aug;
9:131.
PMID: 19691829
Background: Current guidelines on the management of urinary tract infection recommend treating febrile urinary tract infection or acute pyelonephritis with antimicrobials for at least 14 days. Few randomized trials showed...
10.
Pander J, Gelderblom H, Guchelaar H
Drug Discov Today
. 2007 Dec;
12(23-24):1054-60.
PMID: 18061885
Even though treatment of several types of solid tumours has improved in the past few years with the introduction of the monoclonal antibodies against epidermal growth factor receptor (EGFR) and...